Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction

2014-07-23 21:09:34 | BioPortfolio


To establish and confirm the safety and clinical utility of BTVA applied unilaterally for lung volume reduction in patients with upper lobe predominate heterogeneous severe emphysema.


All subjects meeting the eligibility criteria and who provide written informed consent will be enrolled. Up to 3 segments in either the right or left upper lobe will be treated with a vapor dose of 10 calories per gram of lung tissue (10 cal/g). Targeted lobe for treatment will be based on lobar disease severity.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment




BTVA System


Prince Charles Hospital




Uptake Medical Corp

Results (where available)

View Results


Published on BioPortfolio: 2014-07-23T21:09:34-0400

Clinical Trials [141 Associated Clinical Trials listed on BioPortfolio]

A Pilot Study to Assess Treatment of Patients With Homogeneous Emphysema Using Sequential Segmental Bronchoscopic Thermal Vapor Ablation (NEXT STEP)

This study is a Prospective, single arm, single center pilot study following outcomes for 12 months after initial BTVA treatment. The primary objectives of the study are to prospectively d...

Post-Market BTVA Registry

Bronchoscopic thermal vapor ablation using Uptake Medical Technology Inc.'s InterVapor System is indicated for treatment of patients with heterogeneous upper lobe emphysema. This study is ...

Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

The purpose of this study is to determine the effective dose of the Aeris BLVR System in patients with advanced emphysema.

Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

The purpose of this study is to evaluate the safety and efficacy of the Aeris BLVR System in patients with advanced emphysema.

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema

This trial is for men and women between the ages of 40 and 74 who have a confirmed diagnosis of emphysema. The objective of the trial is to determine the safety and effectiveness of the IB...

PubMed Articles [8035 Associated PubMed Articles listed on BioPortfolio]

Bronchoscopic Thermal Vapor Ablation: Best Practice Recommendations from an Expert Panel on Endoscopic Lung Volume Reduction.

Bronchoscopic thermal vapor ablation (BTVA) represents one of the endoscopic lung volume reduction (ELVR) techniques that aims at hyperinflation reduction in patients with advanced emphysema to improv...

Bronchoscopically Delivered Thermal Vapor Ablation of Human Lung Lesions.

The discovery that early diagnosis can reduce the mortality of lung cancer provides firm evidence that early surgical intervention is effective. However, surgical resection is available only to those ...

Free Desmosine is a Sensitive Marker of Smoke-Induced Emphysema.

While the elastin-specific crosslinks, desmosine and isodesmosine (DID), are increased in blood, urine, and sputum of patients with clinically documented pulmonary emphysema, the usefulness of DID in ...

The effect of emphysema on readmission and survival among smokers with heart failure.

Heart Failure (HF) and chronic obstructive pulmonary disease (COPD) are morbid diseases that often coexist. In patients with coexisting disease, COPD is an independent risk factor for readmission and ...

Inflammatory Signature in Lung Tissues in Patients with Combined Pulmonary Fibrosis and Emphysema.

The etiology and inflammatory profile of combined pulmonary fibrosis and emphysema (CPFE) remain uncertain currently.

Medical and Biotech [MESH] Definitions

Enlargement of air spaces distal to the TERMINAL BRONCHIOLES where gas-exchange normally takes place. This is usually due to destruction of the alveolar wall. Pulmonary emphysema can be classified by the location and distribution of the lesions.

A pathological accumulation of air in tissues or organs.

Adrenergic beta-2 agonist used as bronchodilator for emphysema, bronchitis and asthma.

Presence of air or gas in the subcutaneous tissues of the body.

Presence of air in the mediastinal tissues due to leakage of air from the tracheobronchial tree, usually as a result of trauma.

More From BioPortfolio on "Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction"

Quick Search


Relevant Topics

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...

Searches Linking to this Trial